Have a feature idea you'd love to see implemented?
Let us know!
ESPR Esperion Therapeutics Inc
Price (delayed)
$2.47
Market cap
$486.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.62
Enterprise value
$901.54M
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make
Highlights
ESPR's revenue has surged by 187% year-on-year and by 6% since the previous quarter
Esperion Therapeutics's EPS has surged by 74% YoY and by 26% QoQ
The quick ratio has grown by 12% YoY but it has contracted by 10% from the previous quarter
The equity has increased by 10% YoY but it has decreased by 8% QoQ
Esperion Therapeutics's debt has increased by 5% YoY
Key stats
What are the main financial stats of ESPR
Market
Valuations
Earnings
Shares outstanding
197.04M
Market cap
$486.68M
Enterprise value
$901.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.05
Revenue
$295.45M
EBIT
-$28.89M
EBITDA
-$28.84M
Free cash flow
-$26.08M
Per share
Balance sheet
Liquidity
EPS
-$0.62
Free cash flow per share
-$0.13
Book value per share
-$1.89
Revenue per share
$1.52
TBVPS
$1.61
Total assets
$314.11M
Total liabilities
$684.32M
Debt
$559.59M
Equity
-$370.21M
Working capital
$141.68M
Debt to equity
-1.51
Current ratio
1.85
Quick ratio
1.28
Net debt/EBITDA
-14.38
Margins
Efficiency
Dividend
EBITDA margin
-9.8%
Gross margin
81.6%
Net margin
-29.4%
Operating margin
5.6%
Return on assets
-27.9%
Return on equity
N/A
Return on invested capital
-5.4%
Return on capital employed
-19.5%
Return on sales
-9.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ESPR stock price
How has the Esperion Therapeutics stock price performed over time
Intraday
2.49%
1 week
17.62%
1 month
19.9%
1 year
107.56%
YTD
-17.39%
QTD
49.7%
Financial performance
How have Esperion Therapeutics's revenue and profit performed over time
Revenue
$295.45M
Gross profit
$241.03M
Operating income
$16.46M
Net income
-$86.77M
Gross margin
81.6%
Net margin
-29.4%
ESPR's revenue has surged by 187% year-on-year and by 6% since the previous quarter
The company's operating income has surged by 111% YoY
ESPR's operating margin has surged by 104% year-on-year
Esperion Therapeutics's net margin has surged by 85% YoY and by 17% QoQ
Growth
What is Esperion Therapeutics's growth rate over time
Valuation
What is Esperion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.05
Esperion Therapeutics's EPS has surged by 74% YoY and by 26% QoQ
The equity has increased by 10% YoY but it has decreased by 8% QoQ
ESPR's revenue has surged by 187% year-on-year and by 6% since the previous quarter
The price to sales (P/S) is 87% lower than the 5-year quarterly average of 12.9 and 9% lower than the last 4 quarters average of 1.8
Efficiency
How efficient is Esperion Therapeutics business performance
Esperion Therapeutics's return on sales has surged by 93% YoY and by 33% QoQ
The return on invested capital has surged by 81% year-on-year and by 31% since the previous quarter
The return on assets has surged by 68% year-on-year and by 18% since the previous quarter
Dividends
What is ESPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ESPR.
Financial health
How did Esperion Therapeutics financials performed over time
The total assets is 54% less than the total liabilities
The total assets has grown by 42% YoY but it has contracted by 11% from the previous quarter
The company's current ratio rose by 17% YoY but it fell by 6% QoQ
ESPR's debt to equity is down by 16% year-on-year but it is up by 7% since the previous quarter
The equity has increased by 10% YoY but it has decreased by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.